Cargando…

Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer

Background: High tumor mutational burden (TMB-H) has been reported as a predictive marker to immunotherapy or prognostic marker in various tumor types. However, there has been little study of the role of TMB-H in advanced biliary tract cancer (BTC). Methods: We analyzed 119 advanced BTC patients who...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hongsik, Kim, Hana, Kim, Ryul, Jo, Hyunji, Kim, Hye Ryeon, Hong, Joohyun, Park, Joon Oh, Park, Young Suk, Kim, Seung Tae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646759/ https://www.ncbi.nlm.nih.gov/pubmed/34855561 http://dx.doi.org/10.1177/15330338211062324

Ejemplares similares

HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer
por: Kim, Hongsik, et al.
Publicado: (2022)

Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer
por: Kim, Hongsik, et al.
Publicado: (2022)

The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers
por: Kim, Hye Ryeon, et al.
Publicado: (2021)

Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach
por: Kim, Hana, et al.
Publicado: (2021)

The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation
por: Jeong, Sun Young, et al.
Publicado: (2023)

Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI
por: Kim, Hye Ryeon, et al.
Publicado: (2023)

Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors
por: Kim, Hana, et al.
Publicado: (2021)

The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer
por: Lee, Su Jin, et al.
Publicado: (2018)

The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC)
por: Heo, Mi Hwa, et al.
Publicado: (2017)

Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing()
por: Yoo, Kwai Han, et al.
Publicado: (2016)

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
por: Kim, Hana, et al.
Publicado: (2021)

Tumor mutation burden in gastro-entero-pancreatic-neuroendocrine neoplasms
por: Jeong, Sun Young, et al.
Publicado: (2023)

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Long-Term Breast Cancer Outcomes of Pregnancy-Associated Breast Cancer (PABC) in a Prospective Cohort
por: Jo, Hyunji, et al.
Publicado: (2022)

Identification of potential biomarkers for diagnosis of pancreatic and biliary tract cancers by sequencing of serum microRNAs
por: Kim, Kwondo, et al.
Publicado: (2019)

Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Vimentin-Positive Circulating Tumor Cells as Diagnostic and Prognostic Biomarkers in Patients with Biliary Tract Cancer
por: Han, Sung Yong, et al.
Publicado: (2021)

Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
por: Kang, Junho, et al.
Publicado: (2020)

Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer
por: Seo, Hye-Rim, et al.
Publicado: (2022)

Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial
por: Kim, Seung Tae, et al.
Publicado: (2019)

Risks of colorectal cancer and biliary cancer according to accompanied primary sclerosing cholangitis in Korean patients with ulcerative colitis: a nationwide population-based study
por: Oh, Eun Hye, et al.
Publicado: (2023)

Therapeutic implication of HER2 in advanced biliary tract cancer
por: Nam, Ah-Rong, et al.
Publicado: (2016)

Predictive Factors of Biliary Tract Cancer in Anomalous Union of the Pancreaticobiliary Duct
por: Park, Jin-Seok, et al.
Publicado: (2016)

PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA
por: Kim, Seung Tae, et al.
Publicado: (2015)

Intraductal papillary mucinous neoplasm of the biliary tract with cardiac metastasis: A case report
por: Lee, Joo Hyung, et al.
Publicado: (2021)

Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
por: Park, Joon Oh, et al.
Publicado: (2015)

Diagnostic Role of Bile Pigment Components in Biliary Tract Cancer
por: Ahn, Keun Soo, et al.
Publicado: (2023)

A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma
por: Jo, Hyunji, et al.
Publicado: (2022)

Age-Specific Cutoffs of the Sysmex UF-1000i Automated Urine Analyzer for Rapid Screening of Urinary Tract Infections in Outpatients
por: Kim, Hyunji, et al.
Publicado: (2019)

Hyperthermia associated with biliary obstruction during living donor liver transplantation
por: Kang, Hyeryung, et al.
Publicado: (2018)

A Case of Biliary Cystadenocarcinoma
por: Suh, Jeong III, et al.
Publicado: (1997)

Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy
por: Cho, Kyoung-Min, et al.
Publicado: (2017)

Variation in clinical target volume delineation in postoperative radiotherapy for biliary tract cancer
por: Koo, Taeryool, et al.
Publicado: (2022)

Somatic Mutations from Whole Exome Sequencing Analysis of the Patients with Biliary Tract Cancer
por: Yoon, Kyong-Ah, et al.
Publicado: (2018)

The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection
por: Kim, Young Saing, et al.
Publicado: (2017)

Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer
por: Park, Chan Su, et al.
Publicado: (2022)

RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin
por: Chun, Jung Won, et al.
Publicado: (2021)

Establishment and characterisation of six human biliary tract cancer cell lines
por: Ku, J-L, et al.
Publicado: (2002)

Establishing Patient-Derived Cancer Cell Cultures and Xenografts in Biliary Tract Cancer
por: Kang, Jihoon, et al.
Publicado: (2023)

Chemotherapy versus Best Supportive Care in Advanced Biliary Tract Carcinoma: A Multi-institutional Propensity Score Matching Analysis
por: Ji, Jun Ho, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_uvfm4eoemnm5prl9nej7vciqbl